Japanese drugmaker Sosei Group Corporation (Sosei Heptares) today announced that its Board of Directors resolved to change the corporate names of the company and its subsidiaries and the location of the head office of the company. 16 February 2024
The European Commission (EC) has published a report providing an overview of the enforcement of European Union antitrust and merger rules by the EC and EU national competition authorities in the pharmaceutical sector between 2018 and 2022. 12 February 2024
February 9, 2024
Sylentis, a wholly owned subsidiary of Spain’s PharmaMar, (has obtained the results of the Phase III SYL10111_V (tivanisiran) clinical trial for the treatment of dry-eye associated with Sjögren’s syndrome. 11 February 2024
Luye Pharma Group has entered into an agreement with Myung In Pharm, granting the latter the exclusive rights to commercialize rivastigmine twice weekly transdermal patch in South Korea. 7 February 2024
The impact of the Corporate Transparency Act on healthcare organizations, increased scrutiny by regulators of private equity investments in healthcare, and the subsectors that are seeing the most mergers and acquisitions, joint ventures and other transactions, are among the topics covered by a new report. 2 February 2024
The US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application and granted Priority Review for Roche subsidiary Genentech’s ALK inhibitor Alecensa (alectinib) as adjuvant treatment following surgery for early-stage lung cancer (NSCLC). 30 January 2024
German pharma and crop sciences major Bayer saw it shares drop more than 6% to 30.37 euros by early afternoon today, on the news that it has been ordered to pay in damages, the highest amount yet in its ongoing litigation linked to an alleged carcinogenic effect of its Roundup weedkiller. 29 January 2024
USA-based gastroenterology specialist Ironwood Pharmaceuticals announced that new data from the Phase III study that evaluated linaclotide in children and adolescents aged 6-17 years with functional constipation were published in The Lancet Gastroenterology & Hepatology. 15 January 2024
Turbine AI, a UK-based biological simulation company building a platform for interpreting human biology in silico, has entered into a collaboration with British pharma major AstraZeneca. 6 January 2024
Denmark’s Union Therapeutics has said that its chief executive, Kim Kjøller, will be making a presentation at the JP Morgan Healthcare Conference on January 8. 5 January 2024
Swedish biotech Calliditas Therapeutics has announced that it has refinanced its debt to the tune of $102 million, shortly after Tarpeyo (budesonide) received regular approval in the USA. 28 December 2023
US pharma major Eli Lilly today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares of POINT Biopharma Global. 20 December 2023
Irish-American specialty pharma company Shorla Oncology and Eversana, a provider of commercialization services to the life sciences industry, have announced the US commercial launch of Jylamvo (methotrexate) oral solution, the first and only oral methotrexate solution approved in the USA for use in adults. 19 December 2023
Today, New York-based Neurogene, a specialist in rare neurological diseases, announced the close of its merger with Neoleukin Therapeutics they announced in July, and has begun trading on the NASDAQ Global Market under the ticker “NGNE.” 19 December 2023
US pharma major AbbVie has announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust pipeline. of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remain. 7 December 2023
Japanese drugmaker Teijin Pharma as enter into an exclusive licensing agreement with Denmark’s Ascendis Pharma regarding the research, development, manufacturing and sales in Japan. 30 November 2023
Two American firms, Evommune and Accutar Biotechnology, have announced a strategic partnership focused on the discovery of novel small molecules in chronic inflammatory diseases. 29 November 2023
Danish diabetes and obesity giant Novo Nordisk today announced the investment of more than 16 billion Danish kroner ($2.3 billion) starting in 2023 to expand the existing production site in Chartres, France, for the current and future product portfolio within serious chronic diseases. 23 November 2023
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
India's Central Drugs Standard Control Organization (CDSCO) has provided a favorable recommendation for its novel antibiotic Miqnaf (nafithromycin) discovered and developed for the treatment of community-acquired bacterial pneumonia (CABP) in adults. 14 October 2024
The Danish Medicines Council (Medicinrådet), responsible for evaluating and recommending new treatments for Denmark’s healthcare system, is facing a significant increase in processing times. 14 October 2024
The South African Health Products Regulatory Authority (SAHPRA) and the Australian Therapeutic Goods Administration (TGA) have signed a Memorandum of Understanding (MoU), which will strengthen collaboration between the two health product regulators. 14 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024